Spots Global Cancer Trial Database for Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)
Official Title: LARK: Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)
Study ID: NCT02984566
Conditions
Interventions
Study Description
Brief Summary: Primary and secondary liver cancer patients will receive liver SABR with or without KIM intervention.
Detailed Description: This is a single arm, phase II, two stage study designed to evaluate cancer targeting accuracy, treatment outcomes and treatment efficiency in 46 patients eligible for SABR for either primary or secondary liver malignancy with the incorporation of KIM.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Nepean Hospital, Penrith, New South Wales, Australia
Westmead Hospital, Westmead, New South Wales, Australia
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Contact Details
Name: Tim Wang, Dr
Affiliation: Westmead Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
